MedTrace Logo

HS-PCI in Locally Advanced Adenocarcinoma of the Lung

NCT02341170 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-04-17

No results posted yet for this study

Summary

The primary aim of this study is evaluate the impact of hippocampal-sparing prophylactic cranial irradiation (HS-PCI) on survival status in patients with nodal-positive (locally advanced) adenocarcinoma by comparing overall survival rates of patients undergoing HS-PCI to that of patients without this intervention. In addition, this study aims to investigate whether HS-PCI is detrimental on neurocognitive function and to evaluate its impact on the patient's quality of life.

Conditions

Interventions

RADIATION

HS-PCI

Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions

Sponsors & Collaborators

  • Universitätsmedizin Mannheim

    lead OTHER

Principal Investigators

  • Frederik Wenz, MD · Department of Radiation Oncology, University Medical Centre Mannheim

  • Frank A. Giordano, MD · Department of Radiation Oncology, University Medical Centre Mannheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-03-31
Completion
2019-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341170 on ClinicalTrials.gov